M.D. ANDERSON CANCER CENTER

DelveInsight's 'HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2024' covers 5+ companies and 5+ pipeline drugs, including clinical and nonclinical profiles, therapeutic assessments by product type, stage, route of administration, and molecule type, highlighting inactive products. Key companies include Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, and Spectrum Pharmaceuticals Inc., with promising therapies like Trastuzumab deruxtecan and Poziotinib.

Iovance Biotherapeutics' MDA-TIL trial terminated due to lack of efficacy, leading to drops in Phase Transition Success Rates (PTSR) in various cancers. Sention Therapeutics' ST-1891 and Armata Pharmaceuticals' APPA-02 trials completed successfully in hypothyroidism and bronchiectasis, respectively, boosting their PTSRs. Karyopharm Therapeutics' Xpovio trial in metastatic melanoma and Worg Pharmaceuticals Hangzhou's WP-1302 trial in Graves' disease were terminated, affecting their PTSRs negatively.